Description
Wegovy 7.2 mg contains semaglutide, a prescription-only, once-weekly injection used to support weight management in adults with obesity where a prescriber considers treatment clinically appropriate. It belongs to a class of medicines called GLP-1 receptor agonists, which help regulate appetite, slow gastric emptying, and increase feelings of fullness, supporting reduced calorie intake and weight loss when used alongside diet and lifestyle changes.
Wegovy 7.2 mg is a higher-strength pre-filled injection pen containing semaglutide. It is intended for patients who have already progressed through the lower Wegovy dose pathway and have been established on the 2.4 mg dose before a prescriber considers whether escalation to 7.2 mg once weekly is suitable.
The 7.2 mg dose is not a starting dose. Patients usually begin treatment at 0.25 mg once weekly and increase gradually under medical supervision to help reduce the likelihood of gastrointestinal side effects. A qualified prescriber may consider increasing to 7.2 mg once weekly only after the patient has been on Wegovy 2.4 mg once weekly for at least 4 weeks and where this is appropriate for their individual treatment plan.
Wegovy works by mimicking the action of the natural GLP-1 hormone, which plays a role in appetite regulation and food intake. By helping patients feel fuller for longer and reducing appetite, Wegovy can support weight loss as part of a structured programme that includes a reduced-calorie diet, increased physical activity, and ongoing lifestyle changes.
The pre-filled pen is designed for subcutaneous injection once weekly, as directed by a healthcare professional. Patients should be shown how to use the pen correctly and should follow the instructions provided in the patient information leaflet. Wegovy should only be used at the dose prescribed and should not be increased without clinical approval.
Wegovy 7.2 mg may be suitable for eligible adults with obesity who require further treatment optimisation after using Wegovy 2.4 mg, subject to clinical assessment. Suitability will depend on factors such as BMI, medical history, current medicines, treatment response, side effects, and overall weight management goals.
Treatment with Wegovy should be monitored by a qualified healthcare professional to assess progress, tolerability, side effects, and ongoing suitability. Wegovy is not suitable for everyone, and a prescription will only be issued where it is considered safe and appropriate following a clinical review.
Overall, Wegovy 7.2 mg offers an additional treatment option for eligible patients already established on Wegovy 2.4 mg who may benefit from dose escalation as part of a supervised weight management programme. It should be used responsibly, alongside diet, physical activity, and regular clinical monitoring.
